<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257165</url>
  </required_header>
  <id_info>
    <org_study_id>60R020.05</org_study_id>
    <nct_id>NCT01257165</nct_id>
  </id_info>
  <brief_title>Driving Simulator Performance After Intake of Zopiclone Sleeping Pills</brief_title>
  <official_title>Driving Simulator Performance Related to Serum Concentrations of the Benzodiazepine-like Hypnotic Zopiclone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SINTEF Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Zopiclone, a widely used hypnotic drug, is frequently found in blood samples taken from
      drivers suspected of driving under the influence. In this study, the investigators aim to
      correlate zopiclone serum concentrations with degrees of driving impairment in healthy
      volunteers by use of a validated driving simulator. The investigators also aim to compare
      their results with the results from a previous study that investigated zopiclone impairment
      of cognitive and psychometric tests.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard deviation of lateral position (SDLP) on road</measure>
    <time_frame>1 h after intake of study medication (during a 30 min driving simulator test session)</time_frame>
    <description>SDLP is a measure that quantifies the extent of car weaving while driving. It has been shown to correlate well with blood alcohol concentrations, and traffic accident risk.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard deviation of lateral position (SDLP) on road</measure>
    <time_frame>3,5 hrs after intake of study medication (during a 30 min driving simulator test session)</time_frame>
    <description>SDLP is a measure that quantifies the extent of car weaving while driving. It has been shown to correlate well with blood alcohol concentrations, and traffic accident risk</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard deviation of lateral position (SDLP) on road</measure>
    <time_frame>6,5 hrs after intake of study medication (during a 30 min driving simulator test session)</time_frame>
    <description>SDLP is a measure that quantifies the extent of car weaving while driving. It has been shown to correlate well with blood alcohol concentrations, and traffic accident risk</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average speed</measure>
    <time_frame>1 h, 3,5 hrs and 6,5 hrs after intake of study medication (during a 30 min driving simulator test session)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard deviation of speed</measure>
    <time_frame>1 h, 3,5 hrs and 6,5 hrs after intake of study medication (during a 30 min driving simulator test session)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of brake pedal pressures</measure>
    <time_frame>1 h, 3,5 hrs and 6,5 hrs after intake of study medication (during a 30 min driving simulator test session)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of accelerator pedal pressures</measure>
    <time_frame>1 h, 3,5 hrs and 6,5 hrs after intake of study medication (during a 30 min driving simulator test session)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steering wheel movement speed and reversal frequency</measure>
    <time_frame>1 h, 3,5 hrs and 6,5 hrs after intake of study medication (during a 30 min driving simulator test session)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Driving behavior at incidents</measure>
    <time_frame>1 h, 3,5 hrs and 6,5 hrs after intake of study medication (during a 30 min driving simulator test session)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical test for impairment (CTI)</measure>
    <time_frame>1,5 hrs, 4 hrs and 7 hrs after intake of study medication (after driving simulator test sessions)</time_frame>
    <description>The Norwegian CTI is a 25-item clinical test that is administered by physicians on subjects suspected of driving under the influence of drugs. The test conclusion is either &quot;impaired&quot; or &quot;not impaired&quot;.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Automobile Driving</condition>
  <arm_group>
    <arm_group_label>Zopiclone 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zopiclone 5 mg pill + placebo pill + placebo drink</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zopiclone 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x zopiclone 5 mg pills + placebo drink</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethanol 0.8 g/L</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 x placebo pills + ethanol 50 g/70 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 x placebo pills + placebo drink</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zopiclone</intervention_name>
    <description>Zopiclone pill 5 or 10 mg, given orally as a single dose.</description>
    <arm_group_label>Zopiclone 5 mg</arm_group_label>
    <arm_group_label>Zopiclone 10 mg</arm_group_label>
    <other_name>Imovane</other_name>
    <other_name>Zopiklon</other_name>
    <other_name>Zopiclon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <description>50 mg per 70 kg body weight, given orally as a single dose</description>
    <arm_group_label>Ethanol 0.8 g/L</arm_group_label>
    <other_name>Alcohol</other_name>
    <other_name>Ethyl alcohol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>Placebo pill identical to zopiclone pill, given orally as a single dose</description>
    <arm_group_label>Zopiclone 5 mg</arm_group_label>
    <arm_group_label>Ethanol 0.8 g/L</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo drink</intervention_name>
    <description>Placebo drink, given orally as a single dose</description>
    <arm_group_label>Zopiclone 5 mg</arm_group_label>
    <arm_group_label>Zopiclone 10 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Caucasian ethnicity

          -  Age 25-35 years

          -  Possession of a driver's licence for at least five years

        Exclusion Criteria:

          -  Score ≥ 2 on the modified Apfel-scale to assess risk for motion sickness(*)

          -  History of driving under the influence of alcohol and/or illicit substances

          -  History or presence of alcohol or illicit drug abuse

          -  Former abnormal reaction to any hypnotic drug

          -  History of strong averse reactions to blood sampling procedures

          -  Regular (daily) intake of any prescribed drug, or intake of grapefruit juice or herbal
             remedies that can influence the metabolism of zopiclone (e.g. St John's wort)

          -  History of severe allergic reactions, or significant mental, cardiovascular, renal or
             hepatic disorder, or other significant disease as judged by the investigators

          -  Detection of any drugs of abuse on pre-session urine drug screening

        (*)Modified Apfel-criteria for prediction of postoperative nausea/vomiting:

          1. Smoker? yes 0, no 1

          2. History of nausea and/or vomiting following surgery, dental treatment, injections or
             similar procedures? yes 0, no 1

          3. History of car sickness after 10 years of age? yes 0, no 1

        A score of two or more points excludes participation.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars J Slørdal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <removed_countries>
    <country>Norway</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Automobile driving</keyword>
  <keyword>Zopiclone</keyword>
  <keyword>Drug safety</keyword>
  <keyword>Traffic accidents</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Zopiclone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

